Phenotypic Heterogeneity of Diabetic Kidney Disease and Its Association With Cardiovascular and Renal Outcomes: Evidence From a Chinese Multicentre Cohort
Aug 2026· Diabetes, obesity and metabolism· Vol 28, pp. 10248 - 10260· 0 citations· 45 references
Medicine
TL;DR
Diabetic kidney disease exhibits substantial clinical heterogeneity, ranging from the classic proteinuric phenotype to the increasingly recognised nonproteinuric phenotype, but cardiovascular, kidney and all‐cause mortality risks across these phenotypes remain incompletely characterised.
Abstract
Diabetic kidney disease (DKD), a major microvascular complication of diabetes, is the leading cause of chronic kidney disease (CKD) and progression to end‐stage kidney disease (ESKD). DKD exhibits substantial clinical heterogeneity, ranging from the classic proteinuric phenotype to the increasingly recognised nonproteinuric phenotype. However, cardiovascular, kidney and all‐cause mortality risks across these phenotypes remain incompletely characterised.
CKD is a major complication of T2DM and a leading cause of end‐stage kidney disease. Because urinary albumin‐to‐creatinine ratio (UACR) and eGFR have recognized limitations, additional biomarkers may help characterize kidney dysfunction. HCY is frequently elevated in CKD and may reflect pathways of renal injury. We eva...
L. Ho, Tien Van Tran, T. Tran et al.· Endocrinology, Diabetes & Me...· 0 citations
Type 1 diabetes mellitus (T1DM) is an autoimmune disease marked by irreversible loss of pancreatic β -cells, which ultimately causes insulin deficiency and hyperglycemia. As of 2022, the global prevalence reached 8.75 million cases [1]. T1DM demonstrates a rising global incidence [2] and marked autoimmune comorbidity (...
Hui Zhao, Yu Wang, Zou-Xi Du et al.· Archives of Medical Science· 0 citations
Microvascular dysfunction contributes to PAD progression, and its detection may facilitate earlier recognition and risk stratification. People with advanced chronic kidney disease (CKD) have a high burden of PAD, yet early detection is limited by disease‐related changes, such as medial calcification. Near‐infrared spec...
E. Bok, Natasha Wiebe, Michael D. Nelson et al.· Clinical Physiology and Func...· 0 citations
Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V).
Fatih Akkaya, Onur Osman Şeker, E. Turkmen et al.· Clinical Cardiology· 0 citations
Kidney diseases, particularly chronic kidney disease (CKD), represent a major and growing health challenge, imposing a substantial economic burden and significantly compromising patients’ quality of life [...]
Susana Coimbra, Flávio Reis, A. Santos-Silva· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
